Autoimmune Diseases Unit, Hospital Universitari Mútua de Terrassa, Terrassa, Catalonia, Spain.
Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC, CSUR) of the Catalan and Spanish Health Systems/Member of ERN-ReCONNET, Hospital Clínic, Barcelona, Catalonia, Spain.
Rheumatology (Oxford). 2024 Feb 6;63(SI):SI46-SI53. doi: 10.1093/rheumatology/kead556.
Catastrophic antiphospholipid syndrome (CAPS) is a severe condition with high mortality. Since its description in 1992, an important effort has been made to improve and disseminate knowledge on CAPS. Most of our current knowledge comes from the studies performed using the CAPS Registry, a database created in 2000 to gather as many cases as possible in order to better define this disease. It has demonstrated that this condition has multiple faces and is often triggered by a precipitating factor that leads to a thrombotic microangiopathy and cytokine storm involving almost any organ of the body. Analysis of the CAPS Registry has also shown that patients receiving anticoagulation, glucocorticoids and plasma exchange and/or IVIG have a better prognosis. However, there are still many unresolved questions. In this review we summarize what is known and what is still a matter of research in this condition.
灾难性抗磷脂综合征(CAPS)是一种死亡率很高的严重疾病。自 1992 年描述以来,人们做出了巨大努力来改善和传播对 CAPS 的认识。我们目前的大部分知识来自于 CAPS 登记处的研究,该数据库创建于 2000 年,目的是收集尽可能多的病例,以便更好地定义这种疾病。它表明这种情况有多种表现形式,通常由导致血栓性微血管病和细胞因子风暴的诱发因素引发,几乎涉及身体的任何器官。对 CAPS 登记处的分析还表明,接受抗凝、糖皮质激素和血浆置换和/或 IVIG 治疗的患者预后更好。然而,仍有许多悬而未决的问题。在这篇综述中,我们总结了该疾病已知的和仍在研究的内容。